UBS analyst Danielle Antalffy upgraded Johnson & Johnson to Buy from Neutral with a price target of $180, up from $167. UBS is upgrading the shares ahead of the December 5 analyst day event given the firm’s increasingly bullish view on the company’s Innovative Medicine business, and expectations for MedTech growth at least in line with the market. The firm views J&J as a top-tier diversified player in healthcare with the company’s commitment to innovation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson upgraded to Buy from Neutral at UBS
- Johnson & Johnson’s (NYSE:JNJ) Revised Earnings Don’t Worry Investors
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
- Johnson & Johnson price target lowered to $170 from $178 at Wells Fargo
- Biden Plans to Boost Drug Production Using Cold-War Era Law